Stock SLRN ACELYRIN, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Acelyrin, Inc.

Equities

SLRN

US00445A1007

Real-time Estimate Cboe BZX
Other stock markets
 01:41:41 2024-05-21 pm EDT 		5-day change 1st Jan Change
4.315 USD +0.35% Intraday chart for Acelyrin, Inc. -8.25% -41.82%
May. 09 Acelyrin, Inc. Announces Ron Oyston to Step Down as Chief People Officer, Effective August 15, 2024 CI
May. 09 Acelyrin, Inc. Announces CEO Changes CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Acelyrin, Inc. Announces Ron Oyston to Step Down as Chief People Officer, Effective August 15, 2024
CI
ACELYRIN, INC. Announces Leadership Transition
GL
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
GL
Acelyrin, Inc. Announces CEO Changes
CI
Acelyrin, Inc. Announces Leadership Transition
CI
ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024
GL
Affibody publishes Annual Report 2023
AQ
North American Morning Briefing : Investors on Edge as High-Stakes Jobs Report Awaited
DJ
Acelyrin, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights
GL
ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights
AQ
North American Morning Briefing : Stocks Struggle After New Records
DJ
Wells Fargo Raises ACELYRIN's Price Target to $13 From $11, Keeps Equalweight Rating
MT
Sector Update: Health Care Stocks Ease Late Afternoon
MT
Sector Update: Health Care
MT
Acelyrin Shares Rise After Lonigutamab Shows Clinical Responses in Thyroid Eye Disease Trial
MT
Transcript : Acelyrin, Inc. - Special Call
Acelyrin : Corporate Presentation
PU
ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease
GL
ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SLRN Stock
  4. News Acelyrin, Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW